Xspray, seeking FDA approval for its Sprycel competitor, settles patent lawsuit with BMS

[cafead]

via Xspray Pharma, before receiving an FDA slapdown in July, had expected to launch its competitor to Bristol Myers Squibb’s leukemia blockbuster Sprycel within the second half of 2023. But as the company works to patch up dosing and manufacturing issues on its lead candidate—dubbed Dasynoc—Xspray has resolved another potential hurdle for its product.

article source